Just reported
From Labcorp's results release of 28 de octubre de 2026; its quarterly report has since been filed.
Actual
3,81B US$
+6,9 % y/y
+2,1 % q/q
Guided
—
No guide given
Actual
3,22 US$
+3,2 % y/y
-12 % q/q
Guided
—
No guide given
Actual
402,1M US$
+1,4 % y/y
-11 % q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Los porcentajes de ingresos son estimaciones para year ended 2025-12-31, no cifras de un informe oficial.
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Estados financieros completos →
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
Construido a partir de los propios informes de Labcorp Holdings Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
370,57 US$-0,5 %cierre 13 nov
Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 30 de octubre de 2026
Labcorp sells medical testing to doctors, hospitals, health plans and patients, plus drug-development laboratory testing to pharmaceutical and biotechnology companies.
Grade A
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 41 trimestres del historial de calificaciones de Labcorp Holdings Inc.. Los otros 39 llegan hasta octubre de 2016.
